HomeCompareEBLU vs JNJ

EBLU vs JNJ: Dividend Comparison 2026

EBLU yields 3.28% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EBLU wins by $4.7K in total portfolio value
10 years
EBLU
EBLU
● Live price
3.28%
Share price
$51.13
Annual div
$1.68
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$405.69
Full EBLU calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — EBLU vs JNJ

📍 EBLU pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEBLUJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EBLU + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EBLU pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EBLU
Annual income on $10K today (after 15% tax)
$279.13/yr
After 10yr DRIP, annual income (after tax)
$344.84/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $358.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EBLU + JNJ for your $10,000?

EBLU: 50%JNJ: 50%
100% JNJ50/50100% EBLU
Portfolio after 10yr
$22.4K
Annual income
$616.74/yr
Blended yield
2.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EBLU
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EBLU buys
0
JNJ buys
0
No recent congressional trades found for EBLU or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEBLUJNJ
Forward yield3.28%3.36%
Annual dividend / share$1.68$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$24.7K$20.0K
Annual income after 10y$405.69$827.78
Total dividends collected$3.7K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EBLU vs JNJ ($10,000, DRIP)

YearEBLU PortfolioEBLU Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,028$328.39$10,676$355.77+$352.00EBLU
2$12,139$338.47$11,407$389.39+$732.00EBLU
3$13,337$348.18$12,198$426.53+$1.1KEBLU
4$14,628$357.51$13,056$467.62+$1.6KEBLU
5$16,018$366.47$13,987$513.12+$2.0KEBLU
6$17,515$375.05$14,998$563.56+$2.5KEBLU
7$19,124$383.26$16,098$619.52+$3.0KEBLU
8$20,854$391.10$17,295$681.69+$3.6KEBLU
9$22,712$398.57$18,599$750.82+$4.1KEBLU
10$24,707$405.69$20,022$827.78+$4.7KEBLU

EBLU vs JNJ: Complete Analysis 2026

EBLUStock

The fund will normally invest at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in the types of securities suggested by its name (i.e., Water Companies). The index is a proprietary rules-based, modified market capitalization weighted, float adjusted index designed to track the overall performance of equity securities of global Water Companies listed on developed country exchanges. The fund is non-diversified.

Full EBLU Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this EBLU vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EBLU vs SCHDEBLU vs JEPIEBLU vs OEBLU vs KOEBLU vs MAINEBLU vs ABBVEBLU vs MRKEBLU vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.